Combined scheduling algorithm for re-entrant batch-processing machines in semiconductor wafer manufacturing
INTERNATIONAL JOURNAL OF PRODUCTION RESEARCH
Authors: Jia, Wenyou; Jiang, Zhibin; Li, You
Abstract
In this paper, a new combined scheduling algorithm is proposed to address the problem of minimising total weighted tardiness on re-entrant batch-processing machines (RBPMs) with incompatible job families in the semiconductor wafer fabrication system (SWFS). The general combined scheduling algorithm forms batches according to parameters from the real-time scheduling simulation platform (ReS2), and then sequences batches through slack-based mixed integer linear programming model (S-MILP), which is defined as batch-oriented combined scheduling algorithm. The new combined scheduling algorithm obtains families' parameters from ReS2 and then sequences these families through modified S-MILP, which is defined as family-oriented combined scheduling algorithm. With rolling horizon control strategy, two combined scheduling algorithms can update RBPMs scheduling continually. The experiments are implemented on ReS2 of SWFS and ILOG CPLEX, respectively. The results demonstrate the effectiveness of our proposed methods.
Expanding the spectrum of pediatric NTRK-rearranged fibroblastic tumors to the central nervous system: A case report with RBPMS-NTRK3 fusion
NEUROPATHOLOGY
Authors: Torre, Matthew; Jessop, Nicholas; Hornick, Jason L.; Alexandrescu, Sanda
Abstract
We report a case of a 20-month-old male presenting with seizures who was found to have a hyperintense lesion on T2-weighted images of magnetic resonance imaging in the left medial temporal lobe that was initially clinically and radiologically thought to be either low-grade glioma or focal cortical dysplasia. Histologic, immunohistochemical and molecular evaluation (array comparative genomic hybridization, Archer fusion panel) of the resection specimen demonstrated a highly infiltrative fibroblastic spindle cell neoplasm with mild nuclear atypia and an RBPMS-NTRK3 fusion. NTRK-fused mesenchymal tumors are known to involve extracranial sites but, to our knowledge, have not been described within the central nervous system. Accurate and timely diagnosis of this entity has important prognostic and therapeutic implications, as NTRK-fused tumors may recur locally and may respond to selective kinase inhibitor therapies.